Andrea Gawrylewski | Aug 4, 2008 | 2 min read
The British High Court's rejection linkurl:last week;http://www.the-scientist.com/blog/display/54909/ of a biotech company's patent on the genetic sequence coding for a therapeutically important protein may be a warning for other biotechs who hold patents on portions of the human genome. The court ruled last week that a patent held by Human Genome Sciences since the mid 1990s was invalid because at the time the company applied for the patent they hadn't demonstrated a practical use. The patent